RxDoctor Payments Data

Sunil Bhandarkar, MD

Ophthalmology · Los Angeles, CANPI 1518977685

Payments from drug & device makers

$3,427in general payments, 2019–2025

Across 175 payments — averaging $19.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$669
  • Sun Pharmaceutical Industries Inc.$584
  • Alcon$345
  • Tarsus Pharmaceuticals, Inc.$328
  • Novartis$319
  • Bausch & Lomb Americas Inc.$281
  • plus $902 from 11 others

What the payments were for

  • Food & beverage$3,427100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,427 in reported general payments places this provider in the 65th percentile of 2,513 ophthalmology providers in California.

See all ophthalmology providers in California

Medicare billing

Part B allowed, 2024
$624,087
Medicare patients
1,004
Services billed
9,834

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine1,018$1,118,987
Cyclosporine679$367,039
XiidraLifitegrast101$102,044
LumiganBimatoprost115$60,736
MieboPerfluorohexyloctane/Pf53$44,218
ProlensaBromfenac Sodium87$31,826
Azelastine Hcl843$31,254
Alphagan PBrimonidine Tartrate49$24,023
CequaCyclosporine15$16,924
Prednisolone Acetate430$15,551
TyrvayaVarenicline Tartrate16$14,030
CombiganBrimonidine Tartrate/Timolol27$13,549
AzoptBrinzolamide22$12,655
RocklatanNetarsudil Mesylat/Latanoprost21$12,200
Latanoprost828$10,038

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Alphagan P, Combigan$669$1,217,2951,209 claims
Bausch & Lomb Americas Inc.Xiidra, Miebo, Vyzulta$281$153,431176 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa, Loteprednol Etabonate$79$34,790114 claims
AlconAzopt, Simbrinza$345$19,17746 claims
Sun Pharmaceutical Industries Inc.Cequa$584$16,92415 claims
Oyster Point Pharma, Inc.Tyrvaya$183$14,03016 claims
NovartisIlevro$319$4,23012 claims
Thea Pharma Inc.Iyuzeh$107$3,42012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 2,513 ophthalmology providers in California.

Other ophthalmology in Los Angeles

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →